Previous research studies found an association between CD34 loss and higher-grade tumours[30, 31] and decreased CD34 expression is also linked to recurrent tumours, a finding confirmed by our data: we observed a very low (<10%) CD34-expression in most of our recurrent cases (3/5, 60%). This evidence concerns the gene CD34 and neoplasm.